Shanghai Allist Pharmaceuticals Co., Ltd.

Overview

Shanghai Allist Pharmaceuticals Co., Ltd. is an innovative pharmaceutical company specializing in the research, development, manufacturing, and commercialization of novel oncology drugs. Founded in 2004, the company is dedicated to addressing unmet clinical needs in the global pharmaceutical market, focusing on tumor treatments.

Therapeutic areas

API / Drug Master Files

Shanghai Allist Pharmaceuticals Co., Ltd. holds 5 active (11 total) FDA Type II Drug Master Files — identifying it as an active-substance / API supplier. Type II DMFs are filed with the FDA to support the use of an active pharmaceutical ingredient in drug applications.

• HYSORPTASEActive2025-04-28
• MC-VC-PAB-MMAEActive2023-08-16
• PAYLOAD-LINKER EXATECAN MESYLATEActive2023-06-07
• PAYLOAD-LINKER MC-MMAFActive2022-02-03
• CHORIONIC GONADOTROPHINActive2016-01-16
• VAL-CIT-PAB-MMAEInactive2024-08-29
• MORPHOLINO GUANINE PHOSPHORAMIDOCHLORIDATEInactive2022-12-28
• MORPHOLINO CYTOSINE PHOSPHORAMIDOCHLORIDATEInactive2022-12-28
• MORPHOLINO THYMINE PHOSPHORAMIDOCHLORIDATEInactive2022-12-28
• “MONOMETHYL AURISTATIN E (MMAE)”Inactive2021-07-22
• PAYLOAD-LINKER VCMMAEInactive2020-05-29

FDA compliance signals

No FDA recalls, Warning Letters, or Form 483 observations are linked to Shanghai Allist Pharmaceuticals Co., Ltd. in our records. PharmaTek screens the full directory against live FDA enforcement data.